To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.
Age ≥ 18 years and < 80 years.
Post-emergent revascularization (PCI or CABG)
Systolic blood pressure < 90 mmHg for >30 minutes, or requiring catecholamine support to maintain systolic blood pressure >90 mmHg
Altered mental status
Acute mechanical complications of infarction (e.g., ventricular septal rupture, acute mitral regurgitation).
Cardiac arrest.
Hypoxic-ischemic brain injury (cerebral injury with fixed and dilated pupils not attributable to medication).
Shock due to other causes (e.g., sepsis, hypovolemia).